Integrin alpha V beta 5

Integrin alpha V beta 5

Integrin alpha V beta 5 詳細

Molecule Name
Integrin alpha-V/beta-5
分子の別称
Integrin alpha V beta 5,ITGAV&ITGB5
Drug Development Progress
治験薬の数3
市販薬剤の数0
研究&開発段階Phase 1 Clinical
ターゲットの別称
Receptors, Vitronectin
バックグランド
Integrin alpha V beta 5 (ITGAV & ITGB5) is expressed on a wide variety of cell types including keratinocytes, fibroblasts, adhesive monocytes, embryonic stem cells, and select endothelium and epithelium. ITGAV & ITGB5 binds ligands containing an RGD motif, notably vitronectin. Growth factors that increase PKC activity, such as VEGF or TGF alpha, promote ITGAV & ITGB5-mediated angiogenesis while alpha V beta 3, which may be expressed in the same cell, responds to FGF-basic and TNF alpha. An inhibitor of both down regulates tumor angiogenesis. During lung inflammation, up regulation of ITGAV & ITGB5 on myofibroblasts or infiltrating lymphocytes may contribute to fibrosis by freeing TGF beta from latency.

Integrin alpha V beta 5 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
RisuteganibALG-1001; AM011; AM-011(Allegro Ophthalmics)Phase 1 ClinicalAllegro Ophthalmics Llc
Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration
詳細
177Lu-FF-10158177Lu-FF-10158Phase 1 ClinicalFujifilm Holdings Corp
Glioblastoma
詳細
NP-011NP-011Phase 1 ClinicalNexell Therapeutics Inc
Myocardial Infarction
詳細